CliffBio
small molecule

BRIDION

SUGAMMADEX SODIUM

Loss of exclusivityJune 2028FDA regulatory exclusivity expiry
CompanyMERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Drug detail

Brand nameBRIDION
Active ingredientSUGAMMADEX SODIUM
StrengthEQ 200MG BASE/2ML (EQ 100MG BASE/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2015
Marketing statusRX

Listed patents

PatentExpiresType
RE44733*PEDJuly 2026—
RE44733January 2026substance, product

Regulatory exclusivity

CodeExpires
PEDJune 2028
NPPDecember 2027

More from MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

BRIDION patent cliff — loss of exclusivity June 2028 | CliffBio